CD79A and colorectal cancer: In study 1, the plasma levels of anti-FadAc IgA were significantly increased in patients with colorectal cancer compared with healthy subjects (1.48 ± 1.07 μg/mL vs. 0.71 ± 0.36 μg/mL, P = 0.001; Fig. 1A).